Patents by Inventor David Novack

David Novack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenicity of a CpG-adjuvanted recombinant plague vaccine
    Patent number: 12364745
    Abstract: The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: July 22, 2025
    Assignees: Dynavax Technologies Corporation, The Government of the United States, as Represented by the Secretary of the Army
    Inventors: Robert S. Janssen, David Novack, Wai Kwan Chung, Andrew M. Glenn, Lucy A. Ward
  • Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Patent number: 12296002
    Abstract: The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: May 13, 2025
    Assignees: MEDIGEN VACCINE BIOLOGICS CORPORATION, DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Tsun-Yung Kuo, Charles Chen, Chung-Chin Wu, Yi-Jiun Lin, Meei-Yun Lin, Yu-Chi Wu, John Darren Campbell, Robert S. Janssen, David Novack, Robert Coffman, Paula Traquina
  • IMMUNOGENICITY OF A CPG-ADJUVANTED RECOMBINANT PLAGUE VACCINE
    Publication number: 20240165215
    Abstract: The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.
    Type: Application
    Filed: June 29, 2023
    Publication date: May 23, 2024
    Applicants: Dynavax Technologies Corporation, The Government of the United States, as Represented by the Secretary of the Army
    Inventors: Robert S. JANSSEN, David Novack, Wai Kwan Chung, Andrew M. Glenn, Lucy A. Ward
  • CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST
    Publication number: 20230218740
    Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coron-avirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: July 13, 2023
    Applicant: Dynavax Technologies Corporation
    Inventors: John D. CAMPBELL, Robert S. JANSSEN, David NOVACK
  • CpG-adjuvanted SARS-CoV-2 virus vaccine
    Patent number: 11684669
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: June 27, 2023
    Assignees: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
  • CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST
    Publication number: 20230110516
    Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: April 13, 2023
    Applicants: Dynavax Technologies Corporation, MEDIGEN VACCINE BIOLOGICS CORPORATION
    Inventors: John D. CAMPBELL, Robert S. JANSSEN, David NOVACK, Tsun-Yung KUO, Charles CHEN, Chung-Chin WU, Yi-Jiun LIN, Meei-Yun LIN, Yu-Chi WU
  • CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST
    Publication number: 20230092650
    Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: March 23, 2023
    Applicants: Dynavax Technologies Corporation, Valneva Austria GmbH
    Inventors: John D. Campbell, Robert S. Janssen, David Novack, Christian Taucher, Christoph Reinisch, Andreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
  • ACTIVE BOOSTER IMMUNIZATION AGAINST TETANUS, DIPHTHERIA AND PERTUSSIS
    Publication number: 20230072809
    Abstract: The present disclosure relates to immunogenic compositions comprising tetanus, diphtheria, and acellular pertussis (Tdap) antigens, and a toll-like receptor 9 (TLR9) agonist, such as oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions may further comprise an aluminum salt adjuvant to which the Tdap antigens are adsorbed. The immunogenic compositions are suitable for active booster immunization against tetanus, diphtheria, and pertussis in an individual in need thereof.
    Type: Application
    Filed: March 9, 2021
    Publication date: March 9, 2023
    Applicants: Dynavax Technologies Corporation, Serum Institute of India Private Limited
    Inventors: John D. CAMPBELL, Robert L. COFFMAN, Randall N. HYER, Robert S. JANSSEN, David NOVACK, Martin GOHLKE, Maureen URBAN, Sunil GAIROLA, Umesh SHALLIGRAM, Manish GAUTUM, Harish RAO
  • SHINGLES VACCINES COMPRISING A TLR9 AGONIST
    Publication number: 20230061403
    Abstract: The present disclosure relates to immunogenic compositions comprising a varicella zoster vims (VZV) glycoprotein E antigen and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against VZV in an individual in need thereof.
    Type: Application
    Filed: March 9, 2021
    Publication date: March 2, 2023
    Applicant: Dynavax Technologies Corporation
    Inventors: John D. CAMPBELL, Randall N. HYER, Robert S. JANSSEN, David NOVACK
  • CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE
    Publication number: 20230038284
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: September 10, 2021
    Publication date: February 9, 2023
    Applicants: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen
  • IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
    Publication number: 20210308257
    Abstract: The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
    Type: Application
    Filed: June 18, 2021
    Publication date: October 7, 2021
    Inventors: Tsun-Yung KUO, Charles CHEN, Chung-Chin WU, Yi-Jiun LIN, Meei-Yun Lin, Yu-Chi WU, John Darren CAMPBELL, Robert S. JANSSEN, David NOVACK
  • Windshield washer system
    Publication number: 20070234499
    Abstract: A windshield washer control system comprising a wiper device; a motor connected to the wiper device, the motor being in operative connection with a controller, the controller including a timer; a pump selectively operated by the controller; and a sprayer for dispensing fluid.
    Type: Application
    Filed: April 6, 2006
    Publication date: October 11, 2007
    Inventors: Harold Thibodeau, James Burcar, David Novack